Institutional investors purchased a net $8.3 million shares of RNN during the quarter ended March 2017 and now own 6.02% of the total shares outstanding. This is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 2.9 Million shares of Rexahn Pharmaceuticals In...